This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Patients With Clinically Inactive Disease Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents
Timeframe: Up to 3 years
Percentage of Patients With Partial Remission Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents
Timeframe: Up to 3 years
Percentage of Patients With Complete Response Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents
Timeframe: Up to 3 years
Percentage of Patients With Partial Response Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents
Timeframe: Up to 3 years
Percentage of Patients With Poor Response Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents
Timeframe: Up to 3 years
Percentage of Patients With Clinically Inactive FMF Disease After Completing Treatment With Canakinumab
Timeframe: Up to 3 years
Percentage of Patients With Complete Remission/Response in Still's Disease After Completing Treatment With Canakinumab
Timeframe: Up to 3 years
Percentage of Patients who are Taking Canakinumab and Stopped or Significantly Tapered Administration of Steroids
Timeframe: Up to 3 years
Percentage of Patients who Discontinued Canakinumab 6 Months After Initiation by Reason for Discontinuation
Timeframe: 6 months